Pivotal bioVenture Partners Fund I, L.P. is Director at Inozyme Pharma, Inc. (INZY). They have made 1 open-market trade across 1 company since 2023, most recently 2023-08-01.
CIK 0001695076
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $571K since 2023, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| INZY | BUY | 2023-08-01 | 2023-08-03 | $4.80 | $571K | -4.4% | -4.4% | -42.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.